Literature DB >> 1721416

FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation.

A G Tzakis1, K Abu-Elmagd, J J Fung, E J Bloom, B Nour, F Greif, T E Starzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1721416      PMCID： PMC2987616     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  7 in total

1.  The side effects of FK 506 in humans.

Authors:  R Shapiro; J J Fung; A B Jain; P Parks; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.

Authors:  J J Fung; S Todo; A Tzakis; A Demetris; A Jain; K Abu-Elmaged; M Alessiani; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

Review 3.  Graft-versus-host disease.

Authors:  J L Ferrara; H J Deeg
Journal:  N Engl J Med       Date:  1991-03-07       Impact factor: 91.245

Review 4.  Cyclosporine treatment of chronic graft-versus-host disease following allogeneic bone marrow transplantation.

Authors:  K M Sullivan; M F Siadak; R P Witherspoon
Journal:  Transplant Proc       Date:  1990-06       Impact factor: 1.066

5.  Thalidomide for graft-versus-host disease.

Authors:  G B Vogelsang; G W Santos; O M Colvin; T Chen
Journal:  Lancet       Date:  1988-04-09       Impact factor: 79.321

6.  Predictors of death from chronic graft-versus-host disease after bone marrow transplantation.

Authors:  J R Wingard; S Piantadosi; G B Vogelsang; E R Farmer; D A Jabs; L S Levin; W E Beschorner; R A Cahill; D F Miller; D Harrison
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

7.  Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.

Authors:  K M Sullivan; H M Shulman; R Storb; P L Weiden; R P Witherspoon; G B McDonald; M M Schubert; K Atkinson; E D Thomas
Journal:  Blood       Date:  1981-02       Impact factor: 22.113
  7 in total
  7 in total

1.  Two-year experience with FK 506 in pediatric patients.

Authors:  A G Tzakis; J Reyes; S Todo; B Nour; R Shapiro; M Jordan; J McCauley; J Armitage; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

2.  Tacrolimus in pediatric renal transplantation.

Authors:  R Shapiro; V P Scantlebury; M L Jordan; C Vivas; H A Gritsch; D Ellis; N Gilboa; S Lombardozzi-Lane; W Irish; J J Fung; T R Hakala; R L Simmons; T E Starzl
Journal:  Transplantation       Date:  1996-12-27       Impact factor: 4.939

Review 3.  Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

Authors:  C M Spencer; K L Goa; J C Gillis
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

4.  Renal transplantation at the University of Pittsburgh: the impact of FK506.

Authors:  R Shapiro; M Jordan; V P Scantlebury; C Vivas; H A Gritsch; A S Rao; M Trucco; A Zeevi; A J Demetris; P Randhawa
Journal:  Clin Transpl       Date:  1994

5.  Blood concentration of tacrolimus and age predict tacrolimus-induced left ventricular dysfunction after bone marrow transplantation in adults.

Authors:  Kohko Kanazawa; Masumi Iwai-Takano; Satoru Kimura; Tetsuya Ohira
Journal:  J Med Ultrason (2001)       Date:  2019-12-02       Impact factor: 1.314

Review 6.  The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience.

Authors:  R Shapiro; M L Jordan; V P Scantlebury; C Vivas; H A Gritsch; R J Corry; F Egidi; J McCauley; D Ellis; N Gilboa
Journal:  Clin Transpl       Date:  1995

7.  Treatment of chronic graft-versus-host disease: Past, present and future.

Authors:  Paul J Martin; Yoshihiro Inamoto; Paul A Carpenter; Stephanie J Lee; Mary E D Flowers
Journal:  Korean J Hematol       Date:  2011-09-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.